Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
AIDS and HIV
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - AIDS and HIV
    Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment - (JAMA)
    TopAbstracts in AIDS and HIV 06/22/2009 - (DGNews)
    TopAbstracts in AIDS and HIV 06/08/2009 - (DGNews)
    Supplementary feeding with either ready-to-use fortified spread or corn-soy blend in wasted adults starting antiretroviral therapy in Malawi: randomised, investigator blinded, controlled trial - (BMJ)
    TopAbstracts in AIDS and HIV 05/25/2009 - (DGNews)

    News archive

     Recent webcasts/CME - AIDS and HIV
  • An Individualized Approach to Selecting Initial Antiretroviral Regimens
  • Strategies for Improving Compliance in Patients on HIV Medications

    Webcasts/CME archive

     Recent cases - AIDS and HIV
      Mesothelioma in an HIV/AIDS Patient Without History of Asbestos Exposure: Possible Role For Immunosuppression in Mesothelioma: A Case Report
      Pulmonary Kaposi Sarcoma in a Human Immunodeficiency Virus - Infected Woman: A Case Report
      Penile Kaposi Sarcoma in an HIV Negative Man: A Case Report
      A Rare Case of Intussusception Leading to the Diagnosis of Acquired Immune Deficiency Syndrome: A Case Report
      HIV-Infection and International Travel: Pretravel Patient Assessment and Management

      Cases archive
        




      my personal edition > aids and hiv > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Rilpivirine Shows Improved Lipid Profile Compared With Efavirenz: Presented at IAS

        By Ed Susman

        SYDNEY, AUSTRALIA -- July 25, 2007 -- Total cholesterol and low-density lipoprotein cholesterol significantly increase among HIV patients taking an efavirenz (Sustiva)-based regimen when compared with patients taking a regimen anchored by the investigative rilpivirine (TMC278), researchers said here at the 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention.

        Rilpivirine is a new drug in the non-nucleoside reverse transcriptase inhibitor class of antiretroviral agents.

        "TMC278 resulted in minimal changes in lipid profiles after 1 year of treatment and may have a potential benefit versus efavirenz," said Kiat Ruxrungtham, MD, Professor of Medicine, Chulalongkorn University, Bangkok, Thailand.

        In his oral presentation on July 24th, Dr. Ruxrungtham described the study that examined three different doses of rilpivirine and efavirenz and their metabolic responses in HIV-infected patients over the course of a year.

        "There was a clear increase from baseline in total cholesterol for the efavirenz group of patients but a minimal increase for the TMC278 dose groups," he said.

        He illustrated that the increase for rilpivirine was about 5 mg, but the increase in cholesterol for efavirenz after 48 weeks was about 31 mg, a difference that reached statistical significance at the P <.001 level.

        Similarly, he found a 1-mg increase in low-density lipoprotein cholesterol among the rilpivirine patients, but a 15-mg increase with efavirenz (P <.001).

        There was a 5-mg increase in high-density lipoprotein (HDL) cholesterol with rilpivirine and a 12-mg increase with efavirenz (P <.001).

        Dr. Ruxrungtham found no significant difference between the two treatments in total cholesterol/HDL cholesterol ratio.

        "Mean changes from baseline in glucose levels and insulin sensitivity were minimal and not clinically relevant for both groups," he said.

        Katia Boven, MD, Director, Global Clinical Development, Tibotec, Inc., Yardley, Pennsylvania, said that the company, part of Johnson & Johnson, will begin phase 3 clinical trials later this year using rilpivirine in combination with either Truvada (emtricitabine and tenofovir) or Kivexa (abacavir and lamivudine) compared with efavirenz and the same backbone.


        [Presentation title: The Metabolic Profile of TMC278, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Abstract TUAB105]




      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send